AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Dicerna™ to Present at Evercore ISI 2nd Annual HealthCONx Conference

November 26, 2019 GMT

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 26, 2019--

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Evercore ISI 2 nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 8:20 a.m. EST in Boston.

A live audio webcast of the presentation will be accessible within the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.

About Dicerna™ Pharmaceuticals, Inc.

Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid (RNA) interference (RNAi) to develop medicines that silence genes that cause disease. The Company’s proprietary GalXC™ technology is being applied to develop potent, selective, and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop, and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Novo Nordisk A/S*, Roche*, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com.

* Transactions are subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.

Dicerna™ and GalXC™ are trademarks of Dicerna Pharmaceuticals, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005526/en/

CONTACT: Investors:

Stern Investor Relations, Inc.

Lauren Stival, 212-362-1200

Lauren.stival@sternir.comMedia:

Dicerna Pharmaceuticals, Inc.

Amy Trevvett, 617-612-6253

atrevvett@dicerna.comorSmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH GENETICS PHARMACEUTICAL

SOURCE: Dicerna™ Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 04:05 PM/DISC: 11/26/2019 04:05 PM

http://www.businesswire.com/news/home/20191126005526/en